Veterinary cannabinoid and menthol compositions and methods

Abstract

The present disclosure relates to compositions, including, hydrogel compositions useful as analgesics including cannabinoids and menthol in a composition formulated to be administrable to a non-human animal rectally as a suppository. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

1 .- 20 . (canceled) 
     
     
         21 . A suppository, comprising:
 an effective amount of at least one cannabinoid; and   an effective amount of menthol comprising a stabilized menthol composition   including menthol and at least one menthol stabilizer compound including   undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.   
     
     
         22 . The suppository of  claim 21 , wherein the suppository further includes a disintegrant including at least one of crosscarmellose sodium and sodium starch glycolate. 
     
     
         23 . The suppository of  claim 21 , wherein the at least one cannabinoid includes CBD. 
     
     
         24 . The suppository of  claim 21 , wherein the at least one cannabinoid includes full spectrum hemp oil. 
     
     
         25 . The suppository of  claim 21 , wherein the suppository is a unit dose formulation and the unit dose formulation includes the at least one cannabinoid in an amount ranging from about 100 mg. to about 1500 mg. 
     
     
         26 . The suppository of  claim 21 , wherein the suppository is a unit dose formulation and the unit dose formulation includes the at least one cannabinoid in an amount ranging from about 5 mg. to about 20 mg. 
     
     
         27 . The suppository of  claim 21 , wherein the suppository is a unit dose formulation and the unit dose formulation includes the menthol in an amount ranging from about 30 mg to about 100 mg. 
     
     
         28 . The suppository of  claim 21 , wherein the suppository is a unit dose formulation and the unit dose formulation includes the menthol in an amount ranging from about 800 mg to about 1100 mg. 
     
     
         29 . The suppository of  claim 21 , wherein the suppository has a length ranging from about 3 inches to about 4 inches, a generally circular cross-section having a diameter ranging from about 0.5 inches to about 0.75 inches, 0.5 in. and an end that has a generally tapered or rounded shape. 
     
     
         30 . A suppository, comprising:
 a biocompatible polymer;   a polyalcohol;   an effective amount of at least one cannabinoid; and   an effective amount of menthol, wherein the menthol is included in a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.   
     
     
         31 . The suppository of  claim 30 , wherein the suppository further includes a disintegrant including at least one of crosscarmellose sodium and sodium starch glycolate. 
     
     
         32 . The suppository of 30, wherein the suppository is a unit dose formulation, the at least one cannabinoid includes full spectrum hemp oil, the full spectrum hemp oil in the unit dose formulation is in an amount of from about 5 mg. to about 1500 mg and the menthol in the unit dose formulation is in an amount of from about 30 mg to about 1500 mg. 
     
     
         33 . The suppository of  claim 30 , wherein the suppository is a unit dose formulation, the at least one cannabinoid includes full spectrum hemp oil, the full spectrum hemp oil in the unit dose formulation is in an amount of from about 5 mg. to about 20 mg and the menthol in the unit dose formulation is in an amount of from about 800 mg to about 1100 mg. 
     
     
         34 . A method of treating inflammation in a non-human mammal using a veterinary therapeutic suppository, the veterinary therapeutic suppository being a unit dose formulation comprising:
 a veterinary effective amount of at least one cannabinoid; and   a veterinary effective amount of menthol, wherein the menthol is included in a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid,   the method comprising administering the veterinary therapeutic suppository into a rectal cavity of the non-human mammal.   
     
     
         35 . The method of  claim 34 , wherein the veterinary therapeutic suppository further includes a disintegrant including at least one of crosscarmellose sodium and sodium starch glycolate. 
     
     
         36 . The method of  claim 34 , wherein the veterinary therapeutic suppository is a unit dose formulation, the at least one cannabinoid is full spectrum hemp oil, the full spectrum hemp oil in the unit dose formulation is in an amount of from about 5 mg. to about 1500 mg and the menthol in the unit dose formulation is in an amount of from about 30 mg. to about 1500 mg. 
     
     
         37 . The method of  claim 34 , wherein the at least one cannabinoid is full spectrum hemp oil, the full spectrum hemp oil is in an amount of from about 1 wt % to about 20 wt % and the menthol is in an amount of from about 0.05 wt % to about 20 wt %. 
     
     
         38 . The method of  claim 34 , wherein the at least one cannabinoid is full spectrum hemp oil, and the full spectrum hemp oil in the veterinary therapeutic suppository is in an amount of about 3.0 wt % and the menthol in the veterinary therapeutic suppository is in an amount of about 0.1 wt %. 
     
     
         39 . The method of  claim 34 , wherein the veterinary therapeutic suppository further includes a biocompatible polymer and a polyalcohol. 
     
     
         40 . The method of  claim 39 , wherein the biocompatible polymer is in an amount of from about 1 wt % to about 25 wt % and the polyalcohol is in an amount of from about 1 wt % to about 70 wt %.